Drug Discovery Market Report 2026

Drug Discovery Market Overview

• Drug Discovery market size has reached to $124.11 billion in 2025 • Expected to grow to $250.51 billion in 2030 at a compound annual growth rate (CAGR) of 15.1% • Growth Driver: Healthcare Expenditure Surge Boosts Drug Discovery Market • Market Trend: Innovative Technologies Transforming Drug Discovery Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the drug discovery market include: • Small Molecule (Segmentation By Drug Type) → Expected gain of $73.82 Billion • Large Molecule (Segmentation By Drug Type) → Expected gain of $51.18 Billion

What Is Covered Under Drug Discovery Market?

Drug discovery is the process of identifying biologically active compounds that possess the potential to become therapeutic agents. The drug discovery process involves different phases, from ideation to development to approval. It is used to discover a new clinical drug for treating new, existing, and previously incurable diseases. The main types of drugs in the drug discovery market are small molecule and large molecule. The small molecules are used to identify small molecules with suitable properties for development. Small molecule refers to a low molecular weight drug that can smoothly penetrate cells. The various processes in drug discovery includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The various technologies in drug discovery includes high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and other technologies. The drug discovery is applied in many therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory disease, and other therapeutic areas. The drug discovery is used by pharmaceutical companies, CROs, and other end-users.

What Is The Drug Discovery Market Growth Forecast?

The drug discovery market size is expected to see rapid growth in the next few years. It will grow to $250.51 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to emergence of ai-driven drug discovery platforms, expansion of personalized medicine, integration of omics data in drug design, growth in biopharmaceutical outsourcing, adoption of automation and robotics in laboratories. Major trends in the forecast period include high-throughput screening advancements, targeted drug development, personalized medicine approaches, integration of pharmacogenomics, nanotechnology-enabled drug discovery.

What Is The Driver Of The Drug Discovery Market?

Rising healthcare expenditure is expected to propel the drug discovery market going forward. Countries around the world are spending a major share of their GDP on healthcare expenses which include hospital care, physician and clinical services, other professional services, dental services, other health, residential, and personal care, home health care, nursing care facilities, and continuing care retirement communities, prescription drugs, and others. Drug discovery holds a significant part of the health expenditure, as it is required to treat diseases and prolong life. There is an increasing need for new drugs to treat new diseases. For instance, in October 2024, according to the Centers for Medicare and Medicaid Services, a US-based federal agency, national health expenditure grew 4.1% to $4.5 trillion in 2022, or $13,493 per person, over 2023–32, average national health expenditure growth (5.6%) is projected to outpace that of average GDP growth (4.3%), resulting in an increase in the health spending share of GDP from 17.3 percent in 2022 to 19.7 percent in 2032. Therefore, the rise in healthcare expenditures is driving the growth of the drug discovery industry.

How Will The Drivers Impact Growth In The Global Drug Discovery Market?

• Rising Prevalence of Chronic and Complex Diseases (High) – During the forecast period, the rising prevalence of chronic and complex diseases is expected to become a major growth driver for the drug discovery market by 2030. The increasing burden of chronic and complex diseases is accelerating the demand for innovative therapeutics and advanced drug development programs worldwide. Pharmaceutical and biotechnology companies are expanding their efforts to identify novel treatment pathways for conditions such as cancer, cardiovascular diseases, neurological disorders, and autoimmune diseases. This growing therapeutic demand is encouraging the adoption of advanced screening technologies, molecular modeling tools, and biomarker-based research approaches that improve drug discovery efficiency and accuracy. Additionally, the need for targeted and personalized therapies continues to increase investment in early-stage drug development activities. Collectively, these factors support strong market expansion by reinforcing the importance of continuous therapeutic innovation. • Advancements in Technologies such as AI, Genomics, and Bioinformatics (High) – During the forecast period, the advancements in technologies such as AI, genomics, and bioinformatics are expected to emerge as a major factor driving the expansion of the drug discovery market by 2030. Rapid technological advancements are transforming drug discovery processes by improving the speed, precision, and efficiency of identifying potential drug candidates. Artificial intelligence and machine learning tools enable researchers to analyze vast biological datasets, predict molecular interactions, and optimize compound selection with greater accuracy. At the same time, genomics and bioinformatics technologies are supporting the development of precision medicine approaches by enabling deeper understanding of disease mechanisms and genetic variations. These innovations significantly reduce research timelines and operational costs while enhancing the probability of successful drug development outcomes. • Increasing R&D Investments by Pharmaceutical and Biotechnology Companies (High) – During the forecast period, the increasing R&D investments by pharmaceutical and biotechnology companies are expected to act as a key growth catalyst for the drug discovery market by 2030. Rising investments in pharmaceutical and biotechnology research are significantly strengthening drug discovery activities across global healthcare ecosystems. Companies are allocating substantial resources toward the development of innovative therapeutics, biologics, and next-generation treatment platforms to address evolving patient needs and competitive market pressures. This increase in R&D spending is accelerating the adoption of advanced laboratory technologies, automated screening systems, and integrated discovery platforms that improve research productivity and clinical success rates. Furthermore, strategic collaborations, licensing agreements, and partnerships between biotechnology firms and pharmaceutical companies are supporting broader research capabilities and expanding therapeutic pipelines. Consequently, the expansion of global R&D activities directly supports sustained growth in the drug discovery market.

How Will The Restraints Impact Growth In The Global Drug Discovery Market?

• High Cost and Time-Intensive Drug Development (High) – During the forecast period, the high cost and time-intensive drug development acts as a major restraint for the drug discovery market by significantly increasing the financial burden on pharmaceutical companies. The process of discovering and developing a new drug can take over a decade and require billions of dollars in investment. Extensive preclinical studies, clinical trials, and regulatory approvals add to both time and cost constraints. Smaller firms and startups often struggle to sustain such long development cycles, limiting innovation. As a result, the high risk of failure combined with heavy capital requirements slows overall market growth. • High Failure Rate in Clinical Trials (High) – During the forecast period, the high failure rates in clinical trials represent a critical restraint for the drug discovery market by reducing the success probability of potential drug candidates. A large proportion of compounds fail during Phase II and Phase III trials due to lack of efficacy or safety concerns. This leads to substantial financial losses after significant investment in earlier stages of development. The uncertainty associated with clinical outcomes discourages investment, particularly in high-risk therapeutic areas. Consequently, this high attrition rate limits the number of successful drug launches and impacts market expansion. • Stringent Regulatory Requirements (High) – During the forecast period, the stringent regulatory requirements act as a significant restraint for the drug discovery market by imposing complex approval processes and compliance standards. Regulatory authorities such as the FDA and EMA require extensive data on safety, efficacy, and quality before granting approvals. This increases the duration and cost of drug development while also adding administrative burdens. Frequent changes in regulatory policies further complicate the approval pathway for companies. As a result, strict regulations delay product launches and create barriers for new entrants, thereby hindering market growth.

Key Players In The Global Drug Discovery Market

Major companies operating in the drug discovery market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Thermo Fisher Scientific Inc., WuXi AppTec Group, GlaxoSmithKline plc, Eli Lilly and Company, Laboratory Corporation of America Holdings, Evotec SE, Eurofins Scientific SE, Agilent Technologies Inc., Sanofi S.A., Charles River Laboratories International Inc., Pharmaron Ltd., Viva Biotech Ltd., Albany Molecular Research Inc., Schrödinger Inc., BioDuro Ltd., Aptuit LLC, Selvita S.A., Sygnature Discovery Limited, Jubilant Biosys Limited, Gero Limited, Domainex Ltd., Verge Genomics lnc., Aqemia SAS, BenevolentAI Limited, EPIVAX INC., ProteinQure lnc., Synlogic Inc., ChemPartner Co. Ltd., WuXi Biologics lnc., Abzena plc, Lonza Group Ltd., Catalent lnc., Recursion Pharmaceuticals Inc.

Global Drug Discovery Market Trends and Insights

Major companies operating in the drug discovery market are coming up with various new technologies, such as AI, imaging technology, and others, to reduce the time required for drug discovery. The imaging technology enables non-invasive biological activities occurring within organisms in response to medications to be visualized, characterized, and quantified. These methods, which make use of the strengths of either probes or tissue itself, are crucial for understanding diseases and finding new treatments. For instance, in May 2023, Google Cloud recently launched two new AI-powered tools, the Target and Lead Identification Suite and the Multiomics Suite, to accelerate drug discovery and precision medicine. These tools are designed to help biotech and pharmaceutical companies advance drug discovery and precision medicine. The Target and Lead Identification Suite assists in identifying the function of amino acids and proteins, while the Multiomics Suite accelerates the discovery and interpretation of genomic data, aiding in the design of precision treatments.

What Are Latest Mergers And Acquisitions In The Drug Discovery Market?

In July 2024, Iktos, a France-based pharmaceutical and biotech company, acquired Synsight for an undisclosed amount. This acquisition aims to enhance Iktos's existing platform by integrating Synsight's advanced technologies, particularly its MT BenchTM system for high-performance screening of biological interactions. Synsight is a France-based biotechnology company.

What Defines the Drug Discovery Market?

The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drug Discovery Market Report 2026?

The drug discovery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.